Roche touts less oner­ous sched­ule for its in-the-eye in­jec­tion faricimab, hop­ing to sweet­en the sales pitch over Eylea

Re­gen­eron has made its name on the back of wet AMD drug Eylea, but the block­buster’s dos­ing sched­ule of in­to-the-eye shots every eight weeks is no cake­walk for pa­tients. Roche, look­ing to take the fight to Eylea with faricimab, thinks it has a lighter sched­ule that could help sway physi­cians.

Rough­ly half of pa­tients across four Phase III tri­als el­i­gi­ble for ex­tend­ed dos­ing of faricimab were able to be treat­ed every four months af­ter one year, sub­sidiary Genen­tech an­nounced Fri­day, and near­ly 75% could take the ex­per­i­men­tal drug every three months. Roche has al­ready prepped a hefty da­ta pack­age for its hope­ful Eylea com­peti­tor, re­leas­ing trick­ling da­ta from four Phase III tri­als over the last few months in di­a­bet­ic mac­u­lar ede­ma and wet AMD.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER